AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25380294 — intervention group
Group type: EXPERIMENTAL
Intervention: High 25OHD
Number of subjects: 615
Study 25380294 — intervention group
Group type: COMPARATOR
Intervention: Low 25OHD
Number of subjects: 615
Study 25380294 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/vigorous PA
Number of subjects: 615
Study 23785427 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated interactive workshops
Number of subjects: 108
Study 23785427 — intervention group
Group type: COMPARATOR
Intervention: Access to a guideline for acute LBP
Number of subjects: 108
Study 22770793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 2183
Study 19730244 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study 19730244 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211
Study 17024628 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume resistance training (3 sets/station)
Number of subjects: 35
Study 17024628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume resistance training (1 set/station)
Number of subjects: 35
Study 17024628 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with lowest pretraining vascular measures
Number of subjects: 35
Study 15365927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac and opioid analgesics
Number of subjects: 70
Study 15365927 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesics alone
Number of subjects: 70
Study 11672580 — intervention group
Group type: COMPARATOR
Intervention: Hypotensive anesthesia (HYPO‐R: remifentanil, HYPO‐N: nitroglycerin)
Number of subjects: 30
Study 11672580 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive anesthesia (NORMO: propofol and remifentanil)
Number of subjects: 30
Study 11672580 — intervention group
Group type: COMPARATOR
Intervention: Hypotensive anesthesia (HYPO‐R and HYPO‐N)
Number of subjects: 30
Study 9884710 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade
Number of subjects: 120
Study 7841753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligusticum wallichii Mixture (LWM)
Number of subjects: 0
Study 7841753 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2453744 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg, twice daily for 24 hours)
Number of subjects: 10
Study 2453744 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (480 mg, twice daily for 3 weeks)
Number of subjects: 10
Study 2453744 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 2453744 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (acute and long-term treatment)
Number of subjects: 10
Study 31473598 — intervention group
Group type: EXPERIMENTAL
Intervention: EBI plus general counselling
Number of subjects: 210
Study 31473598 — intervention group
Group type: COMPARATOR
Intervention: General counselling alone
Number of subjects: 210
Study 30208396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB)
Number of subjects: 670
Study 30208396 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Exercise (MME)
Number of subjects: 670
Study 30208396 — intervention group
Group type: COMPARATOR
Intervention: Stretching Exercise
Number of subjects: 670
Study 26329656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) with low dosage of fentanyl (15 μg/kg)
Number of subjects: 50
Study 26329656 — intervention group
Group type: COMPARATOR
Intervention: High dosage of fentanyl (30 μg/kg) with normal saline (control group)
Number of subjects: 50
Study 26317510 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment for Performance (P4P) scheme
Number of subjects: 3000
Study 24010549 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate red wine intake (250 mL/day for 4 weeks)
Number of subjects: 41
Study 24010549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no red wine intake)
Number of subjects: 41
Study 21536465 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized helium-3 (HHe) ventilation MRI
Number of subjects: 1
Study 21536465 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized helium-3 (HHe) ADC MRI
Number of subjects: 1
Study 18561360 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 0
Study 18561360 — intervention group
Group type: COMPARATOR
Intervention: Non-preferred hand in advanced stages
Number of subjects: 0
Study 16814635 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-delivered reattribution training
Number of subjects: 70
Study 16814635 — intervention group
Group type: COMPARATOR
Intervention: No reattribution training
Number of subjects: 70
Study 14673053 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of oral paroxetine hydrochloride daily
Number of subjects: 549
Study 14673053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 11184958 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire (4 pages)
Number of subjects: 847
Study 11184958 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium questionnaire (5 pages)
Number of subjects: 847
Study 11184958 — intervention group
Group type: EXPERIMENTAL
Intervention: Long questionnaire (7 pages)
Number of subjects: 847
Study 11184958 — intervention group
Group type: EXPERIMENTAL
Intervention: All questionnaires
Number of subjects: 847
Study 8818199 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (16g leucine, 2g isoleucine, 2g valine per day)
Number of subjects: 17
Study 8818199 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 17
Study 8818199 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study 8818199 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 17
Study 1424424 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 to 60 mg)
Number of subjects: 25
Study 6731879 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg of cimetidine only
Number of subjects: 60
Study 6731879 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of metoclopramide only
Number of subjects: 60
Study 6731879 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg of cimetidine and 0.15 mg/kg of metoclopramide
Number of subjects: 60
Study 6731879 — intervention group
Group type: COMPARATOR
Intervention: Normal saline only
Number of subjects: 60
Study 31087542 — intervention group
Group type: EXPERIMENTAL
Intervention: TCZ‐SC 162 mg qw
Number of subjects: 401
Study 31087542 — intervention group
Group type: COMPARATOR
Intervention: TCZ‐SC 162 mg q2w
Number of subjects: 401
Study 28693515 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐h communication skills training (CST) program
Number of subjects: 60
Study 28693515 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 60
Study 26686682 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M)
Number of subjects: 3698
Study 26686682 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 3698
Study 26686682 — intervention group
Group type: COMPARATOR
Intervention: Azilsartan medoxomil (AZL-M) and Ramipril
Number of subjects: 3698
Study 24317556 — intervention group
Group type: EXPERIMENTAL
Intervention: D-fortified group (n = 55)
Number of subjects: 55
Study 24317556 — intervention group
Group type: COMPARATOR
Intervention: D-placebo group (n = 54)
Number of subjects: 55
Study 20965941 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/day
Number of subjects: 24
Study 20965941 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 18602824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (5 g, twice daily for 4 weeks)
Number of subjects: 16
Study 16429095 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who responded to antidepressant therapy (defined as at least a 40% reduction in depressive symptoms)
Number of subjects: 0
Study 16429095 — intervention group
Group type: COMPARATOR
Intervention: Parents who did not respond to antidepressant therapy
Number of subjects: 0
Study 16429095 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who responded to treatment
Number of subjects: 0
Study 16429095 — intervention group
Group type: COMPARATOR
Intervention: Parents who did not respond to treatment
Number of subjects: 0
Study 12855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation (V-sessions)
Number of subjects: 33
Study 12855089 — intervention group
Group type: COMPARATOR
Intervention: Static blank screen (B-sessions)
Number of subjects: 33
Study 11195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 sleep preceded by alpha
Number of subjects: 0
Study 11195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 sleep preceded by theta
Number of subjects: 0
Study 11195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking state
Number of subjects: 0
Study 11195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 1 sleep (alpha-theta transition)
Number of subjects: 0
Study 11195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 2 sleep
Number of subjects: 0
Study 11195715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare stimuli
Number of subjects: 0
Study 8810684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) 3mg/kg per day
Number of subjects: 340
Study 8810684 — intervention group
Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 340
Study 8810684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 340
Study 1426499 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone pessaries 100 mg b.d. from 48 hours prior to embryo transfer and continued throughout the luteal phase
Number of subjects: 245
Study 1426499 — intervention group
Group type: COMPARATOR
Intervention: No luteal support
Number of subjects: 245
Study 1426499 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone pessaries
Number of subjects: 245
Study 3900811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintropium bromide
Number of subjects: 30
Study 3900811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3900811 — intervention group
Group type: COMPARATOR
Intervention: Rociverine
Number of subjects: 30
Study 30504510 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD tapering by 50% (arm 2)
Number of subjects: 146
Study 30504510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping DMARD after tapering (arm 3)
Number of subjects: 146
Study 30504510 — intervention group
Group type: COMPARATOR
Intervention: Full-dose DMARD treatment
Number of subjects: 146
Study 30504510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering and stopping DMARD in low-risk relapse group
Number of subjects: 146
Study 30504510 — intervention group
Group type: EXPERIMENTAL
Intervention: Average reduction of DMARD costs per patient
Number of subjects: 146
Study 30359537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NaNO3)
Number of subjects: 17
Study 30359537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 17
Study 27259714 — intervention group
Group type: EXPERIMENTAL
Intervention: MM-302 plus trastuzumab
Number of subjects: 250
Study 27259714 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy of physician's choice plus trastuzumab (gemcitabine, capecitabine, or vinorelbine)
Number of subjects: 250
Study 25249361 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy for 12 weeks
Number of subjects: 209
Study 25249361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 209
Study 25249361 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment
Number of subjects: 209
Study 22512435 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (1000 mg testosterone undecanoate intramuscular injections at 0, 6, and 12 weeks)
Number of subjects: 67
Study 22512435 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 67
Study 22512435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 20131268 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids alone
Number of subjects: 124
Study 20131268 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide pulses
Number of subjects: 124
Study 20131268 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 124
Study 20131268 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 124
Study 20131268 — intervention group
Group type: COMPARATOR
Intervention: Deaths
Number of subjects: 124
Study 20131268 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 124
Study 18045765 — intervention group
Group type: COMPARATOR
Intervention: GI, unfilled teeth (control)
Number of subjects: 72
Study 18045765 — intervention group
Group type: EXPERIMENTAL
Intervention: GII, Endofill+gutta‐percha
Number of subjects: 72
Study 18045765 — intervention group
Group type: EXPERIMENTAL
Intervention: GIII, Sealer 26+gutta‐percha
Number of subjects: 72
Study 18045765 — intervention group
Group type: EXPERIMENTAL
Intervention: GIV, AH Plus+gutta‐percha
Number of subjects: 72
Study 18045765 — intervention group
Group type: EXPERIMENTAL
Intervention: GV, Epiphany+gutta‐percha
Number of subjects: 72
Study 18045765 — intervention group
Group type: EXPERIMENTAL
Intervention: GVI, Epiphany+Resilon
Number of subjects: 72
Study 15949795 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% diclofenac
Number of subjects: 32
Study 15949795 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 32
Study 15949795 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 32
Study 15949795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac withdrawal in group A
Number of subjects: 32
Study 15949795 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group B
Number of subjects: 32
Study 12385927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic alpha-blockers
Number of subjects: 234
Study 12385927 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic alpha-blockers
Number of subjects: 234
Study 10084524 — intervention group
Group type: EXPERIMENTAL
Intervention: Accident victims
Number of subjects: 210
Study 10084524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 7718371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (4.4 micrograms kg‐1 min‐1)
Number of subjects: 22
Study 7718371 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 1801386 — intervention group
Group type: EXPERIMENTAL
Intervention: Otovent treatment for two weeks
Number of subjects: 100
Study 1801386 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 100
Study 7230728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (1.5 g/day)
Number of subjects: 3
Study 7230728 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3
Study 7230728 — intervention group
Group type: COMPARATOR
Intervention: Phenprocoumon treatment
Number of subjects: 3
Study 7230728 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups after one year
Number of subjects: 3
Study 30411377 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 100
Study 30411377 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 100
Study 30411377 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 100
Study 28422459 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean power toothbrush
Number of subjects: 144
Study 28422459 — intervention group
Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 144
Study 26446485 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 336
Study 26446485 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat mass index (FMI)
Number of subjects: 336
Study 26446485 — intervention group
Group type: EXPERIMENTAL
Intervention: Central fat mass index (android FMI)
Number of subjects: 336
Study 26446485 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral fat mass index (gynoid FMI)
Number of subjects: 336
Study 26446485 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicular fat mass index (appendicular FMI)
Number of subjects: 336
Study 23911077 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb task specific repetitive training (TSRT) guided by a robotic orthosis
Number of subjects: 15
Study 23911077 — intervention group
Group type: COMPARATOR
Intervention: Upper limb task specific repetitive training (TSRT) guided by a physical therapist
Number of subjects: 15
Study 21822018 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnolia gum
Number of subjects: 120
Study 21822018 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Number of subjects: 120
Study 21822018 — intervention group
Group type: COMPARATOR
Intervention: Control gum
Number of subjects: 120
Study 19491796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua Maris nasal spray (thrice daily)
Number of subjects: 50
Study 19491796 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone (Control)
Number of subjects: 50
Study 17955784 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil, Galantamine, Rivastigmine (acetylcholinesterase inhibitors)
Number of subjects: 0
Study 17955784 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (glutamate antagonist)
Number of subjects: 0
Study 17955784 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetylcholinesterase inhibitors or memantine
Number of subjects: 0
Study 12460525 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted, practice‐based intervention involving audit, feedback, and academic detailing
Number of subjects: 60
Study 12460525 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 10601178 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (150 mg/day)
Number of subjects: 29
Study 10601178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10601178 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg acute ingestion)
Number of subjects: 29
Study 8554931 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (5 pmol min-1)
Number of subjects: 6
Study 8554931 — intervention group
Group type: EXPERIMENTAL
Intervention: Big endothelin-1 (50 pmol min-1)
Number of subjects: 6
Study 8554931 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (0.9%; w/v)
Number of subjects: 6
Study 1951544 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (monitored group)
Number of subjects: 377
Study 1951544 — intervention group
Group type: COMPARATOR
Intervention: High-risk prenatal care alone (not monitored group)
Number of subjects: 377
Study 7032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy
Number of subjects: 120
Study 7032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 120
Study 7032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal anal dilatation
Number of subjects: 120
Study 7032489 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection
Number of subjects: 120
Study 31686175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/24 h, transdermally) and galantamine (4 mg, p.o.) combined
Number of subjects: 26
Study 31686175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine alone (7 mg/24 h, transdermally)
Number of subjects: 26
Study 31686175 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine alone (4 mg, p.o.)
Number of subjects: 26
Study 31686175 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 26
Study 31686175 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (4 mg, p.o.)
Number of subjects: 26
Study 30808132 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure based on results of supine roll test
Number of subjects: 100
Study 30808132 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning procedure based on results of lean nystagmus and sitting to supine positioning nystagmus
Number of subjects: 100
Study 28251402 — intervention group
Group type: EXPERIMENTAL
Intervention: BRJ (140 ml concentrated nitrate-rich beetroot juice, 12.5 mmol nitrate)
Number of subjects: 8
Study 28251402 — intervention group
Group type: COMPARATOR
Intervention: PLA (nitrate-deplete beetroot juice, 0.01 mmol nitrate)
Number of subjects: 8
Study 26198373 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² plus vinorelbine 60 mg/m²
Number of subjects: 153
Study 26198373 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine doses per kg LBM
Number of subjects: 153
Study 26198373 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction and/or stop of treatment
Number of subjects: 153
Study 23312874 — intervention group
Group type: EXPERIMENTAL
Intervention: Desires for Alcohol Questionnaire (DAQ‐6)
Number of subjects: 826
Study 21823413 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (body acupuncture, scalp acupuncture, electric acupuncture)
Number of subjects: 148
Study 21823413 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation training
Number of subjects: 148
Study 18240879 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 709
Study 18240879 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 709
Study 16531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (10,000 IU beta-carotene, 200 IU alpha-tocopherol acetate, 250 mg ascorbic acid, 50 microg selenium, 15 mg zinc)
Number of subjects: 17
Study 16531896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16531896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Antioxidant and Placebo)
Number of subjects: 17
Study 15193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 929